SAHPRA warns of increased brain tumour risk with specific contraceptive use
The South African Health Products Regulatory Authority (SAHPRA) has advised that the product information for medroxyprogesterone acetate (MPA) be updated to include revised safety warnings, including the risk of meningioma.

